Misplaced Pages

This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (August 2023) (Learn how and when to remove this message)

Delcath Systems

Traded as	Nasdaq: DCTH
Headquarters	New York City , United States

Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).

Phase III melanoma trial enrolling

• University of Pittsburgh Medical Center
• National Cancer Institute in Bethesda, Maryland
• Albany Medical Center in Albany, New York
• John Wayne Cancer Center in Santa Monica, California
• Moffitt Cancer Center in Tampa, Florida
• Morristown Memorial Hospital in Morristown, New Jersey
• Providence Cancer Center in Portland, Oregon
• St. Luke's Cancer Center of Bethlehem, Pennsylvania
• Swedish Medical Center in Englewood, Colorado
• University of Maryland Medical Center in Baltimore, Maryland
• University of Texas Medical Branch in Galveston, Texas

References

1. "Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma", News-Medical.Net, 20 July 2015, retrieved 6 October 2015
2. "Delcath Expands Phase II Multi-Histology Clinical Trial". businesswire.com.
3. Reddy, Srinevas K.; Kesmodel, Susan B.; Alexander, H. Richard (July 2014). "Isolated hepatic perfusion for patients with liver metastases". Therapeutic Advances in Medical Oncology. 6 (4): 180–194. doi:10.1177/1758834014529175. ISSN 1758-8340. PMC 4107710. PMID 25057304.
4. "Specialty Pharmacy Services: An Overview for Oncology Practices". The Journal of Hematology Oncology Pharmacy. 2 (2). 29 July 2015. ISSN 2164-1161. Archived from the original on 7 October 2015. Retrieved 6 October 2015.

External links

• Delcath official website

This oncology article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Companies listed on the Nasdaq
• Cancer organizations based in the United States
• Hepatology organizations
• Companies based in New York City
• Specialty drugs
• Health care companies based in New York (state)
• Oncology stubs
• Medical company stubs